Cargando…

The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy

Diabetic cardiomyopathy is more prevalent in people with type 2 diabetes mellitus (T2DM) than previously recognized, while often being characterized by diastolic dysfunction in the absence of systolic dysfunction. This likely contributes to why heart failure with preserved ejection fraction is enric...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gopal, Keshav, Chahade, Jadin J., Kim, Ryekjang, Ussher, John R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750477/ https://www.ncbi.nlm.nih.gov/pubmed/33364978 http://dx.doi.org/10.3389/fphys.2020.603247

Ejemplares similares

Myocardial Energy Metabolism in Non-ischemic Cardiomyopathy
por: Greenwell, Amanda A., et al.
Publicado: (2020)

Metabonomic Characteristics of Myocardial Diastolic Dysfunction in Type 2 Diabetic Cardiomyopathy Patients
por: Hao, Mingyu, et al.
Publicado: (2022)

Cardiac-Specific Deletion of Pyruvate Dehydrogenase Impairs Glucose Oxidation Rates and Induces Diastolic Dysfunction
por: Gopal, Keshav, et al.
Publicado: (2018)

Impact of Myocardial Energy Expenditure and Diastolic Dysfunction on One Year Outcome Patients With HFpEF
por: Wang, Yu, et al.
Publicado: (2022)

New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease
por: Almutairi, Malak, et al.
Publicado: (2022)

Predictive Modeling of Secondary Pulmonary Hypertension in Left Ventricular Diastolic Dysfunction
por: Harrod, Karlyn K., et al.
Publicado: (2021)

Association between Diastolic Dysfunction with Inflammation and Oxidative Stress in Females ob/ob Mice
por: Sartori, Michelle, et al.
Publicado: (2017)

Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
por: Borghetti, Giulia, et al.
Publicado: (2018)

Diabetic retinopathy is associated with diastolic dysfunction in type 2 diabetic patients with non-ischemic dilated cardiomyopathy
por: Chung, Yoo-Ri, et al.
Publicado: (2017)

Diabetic Cardiomyopathy: Impact of Biological Sex on Disease Development and Molecular Signatures
por: Toedebusch, Ryan, et al.
Publicado: (2018)

Berberine Could Ameliorate Cardiac Dysfunction via Interfering Myocardial Lipidomic Profiles in the Rat Model of Diabetic Cardiomyopathy
por: Dong, Shifen, et al.
Publicado: (2018)

Left Atrial Strain to Identify Diastolic Dysfunction in Children with Cardiomyopathies
por: Sabatino, Jolanda, et al.
Publicado: (2019)

Association of Asymmetric Dimethylarginine and Diastolic Dysfunction in Patients with Hypertrophic Cardiomyopathy
por: Cordts, Kathrin, et al.
Publicado: (2019)

Cardiovascular Biomarkers and Diastolic Dysfunction in Patients With Chronic Chagas Cardiomyopathy
por: Echeverría, Luis E., et al.
Publicado: (2021)

The Role of Sodium in Diabetic Cardiomyopathy
por: Doliba, Nicolai M., et al.
Publicado: (2018)

The Role of Leukocytes in Diabetic Cardiomyopathy
por: Bajpai, Anamika, et al.
Publicado: (2018)

Repurposing Antidiabetic Drugs for Cardiovascular Disease
por: Schubert, Mario, et al.
Publicado: (2020)

Antidiabetic and Antihyperlipidemic Effects of Methanolic Extract of Leaves of Spondias mombin in Streptozotocin-Induced Diabetic Rats
por: Gobinath, Ramachawolran, et al.
Publicado: (2022)

MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin
por: Dai, Beibei, et al.
Publicado: (2018)

Pyroptosis and Its Regulation in Diabetic Cardiomyopathy
por: Lu, Yafang, et al.
Publicado: (2022)

CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction—A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat
por: Roof, Steve R., et al.
Publicado: (2017)

Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
por: Kawana, Masataka, et al.
Publicado: (2022)

Mitochondrial Dysfunction as Substrate for Arrhythmogenic Cardiomyopathy: A Search for New Disease Mechanisms
por: van Opbergen, Chantal J. M., et al.
Publicado: (2019)

Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes
por: De Blasio, Miles J., et al.
Publicado: (2020)

New Molecular Insights of Insulin in Diabetic Cardiomyopathy
por: Westermeier, Francisco, et al.
Publicado: (2016)

Characterising an Alternative Murine Model of Diabetic Cardiomyopathy
por: Tate, Mitchel, et al.
Publicado: (2019)

Impact of new electrocardiographic criteria in arrhythmogenic cardiomyopathy
por: Hauer, Richard N. W., et al.
Publicado: (2012)

Erratum: Hypertrophic cardiomyopathy: Mutations to mechanisms to therapies
por: Frontiers Production Office,
Publicado: (2022)

Corrigendum: Characterising an Alternative Murine Model of Diabetic Cardiomyopathy
por: Tate, Mitchel, et al.
Publicado: (2021)

Novel Insights Into Molecular Mechanism of Mitochondria in Diabetic Cardiomyopathy
por: Bai, Jing, et al.
Publicado: (2021)

Diabetes outcomes in heart failure patients with hypertrophic cardiomyopathy
por: Mekhaimar, Menatalla, et al.
Publicado: (2022)

Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation
por: Gopal, Keshav, et al.
Publicado: (2023)

Assessment of Diabetic Cardiomyopathy by Cardiovascular Magnetic Resonance T1 Mapping: Correlation with Left-Ventricular Diastolic Dysfunction and Diabetic Duration
por: Shang, Yongning, et al.
Publicado: (2017)

Peripartum Cardiomyopathy Presenting with Predominant Left Ventricular Diastolic Dysfunction: Efficacy of Bromocriptine
por: Ballo, Piercarlo, et al.
Publicado: (2012)

Troponin Mutation Caused Diastolic Dysfunction and Experimental Treatment in Transgenic Mice with Cardiomyopathy
por: Xu, Yang, et al.
Publicado: (2015)

The Association between the Extent of Late Gadolinium Enhancement and Diastolic Dysfunction in Hypertrophic Cardiomyopathy
por: Alis, Deniz, et al.
Publicado: (2021)

Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator
por: Kolijn, Detmar, et al.
Publicado: (2020)

The Drug Candidate BGP-15 Delays the Onset of Diastolic Dysfunction in the Goto-Kakizaki Rat Model of Diabetic Cardiomyopathy
por: Bombicz, Mariann, et al.
Publicado: (2019)

Myocyte [Na(+)](i) Dysregulation in Heart Failure and Diabetic Cardiomyopathy
por: Despa, Sanda
Publicado: (2018)

NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy
por: Luo, Beibei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gpj2ht40qfhqtu8lt523fu0cf7